Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RXRG001
Therapeutic Area : Pharmacology/Toxicology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RiboX IND Clearance for RXRG001, First Circular RNA Therapy
Details : RXRG001 is the first-ever circular RNA therapy candidate, which is currently being evaluated for the treatment of radiation-induced xerostomia and hyposalivation.
Brand Name : RXRG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 25, 2024
Lead Product(s) : RXRG001
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?